A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations

NCT01310036 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

208

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Interventions

DRUG: Erlotinib

Sponsor

Hoffmann-La Roche